zanubrutinib

Zanubrutinib is a targeted cancer therapy designed to treat certain blood cancers, such as mantle cell lymphoma and certain types of leukemia. It works by blocking a protein called Bruton's tyrosine kinase (BTK), which cancer cells need to grow and survive. By inhibiting BTK, zanubrutinib helps slow or stop the progression of cancer. It is taken orally and is usually prescribed by a healthcare provider as part of a treatment plan for specific blood cancers. Its goal is to improve disease control while minimizing side effects compared to some older treatments.